Ambry Genetics to Present at 2021 ACMG Annual Clinical Genetics Meeting
Study shows strong data for finding whether certain genetic variants in the BRCA2 cancer gene may be classified as disease-causing
News provided by
Share this article
Share this article
ALISO VIEJO, Calif., April 13, 2021 /PRNewswire/ Ambry Genetics Corporation (Ambry), a Konica Minolta Precision Medicine (KMPM) company and a leader in clinical diagnostic testing, announced it will be presenting
The Uniform Application of Protein Functional Data has an Impressive Potential to Resolve VUS Rates in BRCA2 based on a study published in
The American Journal of Human Genetics
in collaboration with researchers at the Mayo Clinic, Moffit Cancer, and the University of Utah. Ambry will present an overview of findings at the 2021 ACMG Annual Clinical Genetics Meeting.